Biohaven Ltd.
BHVN
NYSE·Healthcare·Biotechnology·Mkt cap $2.4B
$15.69
▼ -1.07%
P/E
-3.38
Mkt Cap
$2.4B
52-Wk Range
$7.48–$18.57
52-Week Range
$7.48 - $18.57
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 8.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary drug candidates targeting underserved neurological conditions
- Focused pipeline addressing high-unmet medical needs with limited competition
- Clinical-stage development platform enabling rapid advancement of multiple programs
Bear Case
1 risk
- Very high volatility (beta 3.2). Expect 3x market swings. Position size accordingly.
Growth
Stable outlook
Advancement of clinical trials and potential regulatory approvals
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+41.1% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BHVN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.91 vs -$0.76 consensus (-19.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-19.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
7 analysts · 71% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
71%
Hold
14%
Sell
14%
Median Price Target
$11.00
▼ -29.9% vs $15.69
Latest: HC Wainwright · Aug 27, 2026
1 analyst covering
vs Industry
How BHVN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related